Literature DB >> 21289480

Can technological solutions for diabetes replace islet cell function?

Justin M Gregory1, Daniel J Moore.   

Abstract

The central objective of diabetes research and management is to restore the deficient secretion of insulin, thereby restoring a state of euglycemia and minimizing short- and long-term risks associated with poor glucose control. The development of the artificial pancreas seeks to imitate the action of the pancreatic beta cell by employing closed-loop control to respond to glycemic excursions by appropriately infusing appropriate amounts of insulin. This article examines progress towards implementing an artificial pancreas in the context of the pancreatic islet as the ideal model for controlling blood glucose. Physiologic insulin secretion will form our foundation for considering the technical design elements relevant to electromechanically imitating the beta cell. The most recent clinical trials using closed-loop control are reviewed and this modality is compared to other curative approaches including islet cell transplantation and preservation. Finally, the potential of the artificial pancreas as a method to adequately reestablish euglycemia is considered.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21289480      PMCID: PMC3082032          DOI: 10.4161/org.7.1.14028

Source DB:  PubMed          Journal:  Organogenesis        ISSN: 1547-6278            Impact factor:   2.500


  95 in total

1.  The effect of rate and dose of glucose infusion on the acute insulin response in man.

Authors:  M Chen; D Porte
Journal:  J Clin Endocrinol Metab       Date:  1976-06       Impact factor: 5.958

2.  Effect of pulse administration of glucose or glucagon on insulin secretion in vitro.

Authors:  G M Grodsky; L L Bennett; D F Smith; F G Schmid
Journal:  Metabolism       Date:  1967-03       Impact factor: 8.694

3.  Islet cell hormonal responses to hypoglycemia after human islet transplantation for type 1 diabetes.

Authors:  Michael R Rickels; Mark H Schutta; Rebecca Mueller; James F Markmann; Clyde F Barker; Ali Naji; Karen L Teff
Journal:  Diabetes       Date:  2005-11       Impact factor: 9.461

4.  Regulation of rat liver glucose-6-phosphatase gene expression in different nutritional and hormonal states: gene structure and 5'-flanking sequence.

Authors:  D Argaud; Q Zhang; W Pan; S Maitra; S J Pilkis; A J Lange
Journal:  Diabetes       Date:  1996-11       Impact factor: 9.461

5.  Feasibility of automating insulin delivery for the treatment of type 1 diabetes.

Authors:  Garry M Steil; Kerstin Rebrin; Christine Darwin; Farzam Hariri; Mohammed F Saad
Journal:  Diabetes       Date:  2006-12       Impact factor: 9.461

6.  Effect of bicycle exercise on insulin absorption and subcutaneous blood flow in the normal subject.

Authors:  E Ferrannini; B Linde; O Faber
Journal:  Clin Physiol       Date:  1982-02

7.  Pump-induced insulin aggregation. A problem with the Biostator.

Authors:  J R Brennan; S S Gebhart; W G Blackard
Journal:  Diabetes       Date:  1985-04       Impact factor: 9.461

8.  Clinical factors influencing the absorption of 125I-NPH insulin in diabetic patients.

Authors:  K Kølendorf; J Bojsen; T Deckert
Journal:  Horm Metab Res       Date:  1983-06       Impact factor: 2.936

9.  Development of the Biostator Glucose clamping algorithm.

Authors:  A H Clemens; D L Hough; P A D'Orazio
Journal:  Clin Chem       Date:  1982-09       Impact factor: 8.327

10.  Glucose clamping using the Biostator GCIIS.

Authors:  C A Verdonk; R A Rizza; R E Westland; R L Nelson; J E Gerich; F J Service
Journal:  Horm Metab Res       Date:  1980-04       Impact factor: 2.936

View more
  1 in total

Review 1.  Wearable and implantable pancreas substitutes.

Authors:  Leonardo Ricotti; Tareq Assaf; Paolo Dario; Arianna Menciassi
Journal:  J Artif Organs       Date:  2012-09-20       Impact factor: 1.731

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.